With gem/cis for squamous NSCLC.
800 mg IV D1,8 Q3W.
800 mg/50 mL vial
None listed.
Hypomagnesemia (83%), Rash (44%), Vomiting (29%), Diarrhea (16%), Dermatitis (15%), Stomatitis (11%)
Consult the complete prescribing information for a comprehensive list of adverse reactions and their frequencies.
No CYP interactions.
Consult the full prescribing information for pregnancy-related considerations.
Refer to prescribing information for lactation guidance.
Pediatric safety and efficacy information is detailed in the full label.
Dose modifications for organ impairment are specified in the complete prescribing information.
Anti-EGFR IgG1 mAb.
t1/2: ~14 days.
Clinical efficacy and safety data supporting the approval are available in the full prescribing information and from the clinical trials listed below.
Portrazza has FDA-approved indications across the following cancer types covered on CancerDrugEvidence:
Portrazza (necitumumab) is an FDA-approved oncology agent. Refer to the full prescribing information for complete indication details.
Refer to the full prescribing information for dosing schedules, administration instructions, and dose modifications.
Portrazza is a targeted oncology agent. Its full mechanism of action is described in the Clinical Pharmacology section of the prescribing information.
Hypomagnesemia (83%), Rash (44%), Vomiting (29%), Diarrhea (16%), Dermatitis (15%), Stomatitis (11%) Hypomagnesemia 83% Rash 44% Vomiting 29% Diarrhea 16% Dermatitis 15% Stomatitis 11%